InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,631.22
(
0.28%
)
US TECH 100
19,892.00
(
0.50%
)
Dow Jones
40,211.72
(
0.53%
)
Brent Oil
84.09
(
-0.30%
)
Bitcoin
64,813.56
(
-0.06%
)
Post# of 252606
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120052
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: bladerunner1717 post# 132356

Saturday, 12/03/2011 12:21:34 AM

Saturday, December 03, 2011 12:21:34 AM

Post# of 252606

I thought it was generally agreed that the "nukes" would be the backbone of an all-oral HCV treatment. So why is BMY spending money testing its NS5A inhibitor with JNJ's TMC435?

It’s not written in stone that an all-oral HCV cocktail must have a nuke.

Could it be possible to have a three-drug combo, each from a different company? (BMY's NS5A inhibitor, JNJ's PI from Medivir and GILD's nuke from VRUS)?

I don’t see why not, if the clinical data are compelling.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up